We Think Some Shareholders May Hesitate To Increase Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Compensation [Yahoo! Finance]
Protagonist Therapeutics, Inc. (PTGX)
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.protagonist-inc.com
Company Research
Source: Yahoo! Finance
The total compensation is similar to the average for the industry Protagonist Therapeutics' EPS grew by 26% over the past three years while total shareholder loss over the past three years was 21% In the past three years, the share price of Protagonist Therapeutics, Inc. NASDAQ:PTGX ) has struggled to grow and now shareholders are sitting on a loss. However, what is unusual is that EPS growth has been positive, suggesting that the share price has diverged from fundamentals. These are some of the concerns that shareholders may want to bring up at the next AGM held on 20th of June. They could also influence management through voting on resolutions such as executive remuneration. We think shareholders might be reluctant to increase compensation for the CEO at the moment, according to our analysis below. See our latest analysis for Protagonist Therapeutics How Does Total Compensation For Dinesh Patel Compare With Other Companies In The Industry? According to our data, Protagoni
Show less
Read more
Impact Snapshot
Event Time:
PTGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTGX alerts
High impacting Protagonist Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTGX
News
- Protagonist Therapeutics Set to Join S&P SmallCap 600PR Newswire
- Is Protagonist Therapeutics, Inc. (PTGX) a Good Healthcare Stock to Buy? [Yahoo! Finance]Yahoo! Finance
- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $45.00 price target on the stock.MarketBeat
- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.MarketBeat
- Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit ControlAccesswire
PTGX
Earnings
- 5/7/24 - Beat
PTGX
Sec Filings
- 6/26/24 - Form 8-K
- 6/17/24 - Form 4
- 6/11/24 - Form 4
- PTGX's page on the SEC website